<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>pharmaceuticals on 3V.org</title>
    <link>https://3v.org/tags/pharmaceuticals/</link>
    <description>Recent content in pharmaceuticals on 3V.org</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 01 May 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://3v.org/tags/pharmaceuticals/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Ozempic Pill Arrives in the U.S., A Familiar Diabetes Drug Takes a New Form</title>
      <link>https://3v.org/ozempic-pill-arrives-in-the-u.s.-a-familiar-diabetes-drug-takes-a-new-form/</link>
      <pubDate>Fri, 01 May 2026 00:00:00 +0000</pubDate>
      
      <guid>https://3v.org/ozempic-pill-arrives-in-the-u.s.-a-familiar-diabetes-drug-takes-a-new-form/</guid>
      <description>Novo Nordisk is rolling out a tablet version of Ozempic (semaglutide) across the United States starting May 4, bringing a well-known injectable treatment into a pill format. It sounds simple—same drug, different delivery—but in reality, getting a peptide-based therapy into an oral form has been a long-standing scientific hurdle, so this is… kind of a big deal.
For years, Ozempic has been associated with weekly injections, widely prescribed for adults with Type 2 diabetes not just to control blood sugar but also to reduce the risk of serious cardiovascular events like heart attacks and strokes.</description>
    </item>
    
  </channel>
</rss>
